RSV Vaccines Approved!

FDA Approves Abrysvo to Prevent Respiratory Syncytial Virus in Older Adults. Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older. [Read more…]

AREXVY is indicated for active immunization for the prevention of LRTD caused by respiratory syncytial virus in individuals 60 years of age or older. [Read more…]

REMINDER: For APRNs that hold DEA registration (licenses)

Important information regarding the Medication Access and Training Expansion (MATE) Act

The Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) released materials in March 2023 related to the new Medication Access and Training Expansion (MATE) Act. The Act requires new or renewing DEA licensees, as of June 27, 2023, to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

*Please note, you are required to complete this education training regardless of whether you prescribe MAT therapy.

For more information go to the DEA Site:

You can also download the DEA Document here: